论文部分内容阅读
目的研究硫普罗宁与顺铂(DDP)、环磷酰胺(CY)联用的协同作用。方法将48只KM小鼠随机分为6组,除正常组外,其余5组小鼠腹腔内接种腹水瘤细胞株[1]。分为:正常组;空白对照组;阳性组(DDP+CY);腹腔内分别注射生理盐水;联合用药组(硫普罗宁高、中、低组)。观察各组小鼠的腹水生成量,瘤细胞数的变化。结果DDP+CY组、硫普罗宁各剂量组与生理盐水对照组相比可以显著抑制H22腹水瘤小鼠腹水的生成,减少瘤细胞的数量;硫普罗宁联合用药组与DDP+CY组相比腹水生成量降低;硫普罗宁各剂量组全血细胞中WBC与DDP+CY组相比有上升趋势,并基本显现了量效关系;与对照组相比各给药组的血浆ALT、AST、BUN、ALP、CREA水平呈降低趋势,硫普罗宁各剂量组动物血浆ALT、AST、BUN、CREA水平明显降低。结论硫普罗宁有协同抗肿瘤作用,并可以降低化疗产生的肝、肾损伤等不良反应。
Objective To study the synergistic effect of tiopronin with cisplatin (DDP) and cyclophosphamide (CY). Methods 48 KM mice were randomly divided into 6 groups. Except normal group, the other 5 groups were inoculated intraperitoneally with ascites tumor cell line [1]. Divided into: normal group; blank control group; positive group (DDP + CY); intraperitoneal injection of saline; combination group (tiopronin high, medium and low groups). The ascites volume and the number of tumor cells in each group were observed. Results DDP + CY group and tiopronin groups could significantly inhibit the ascites production and the number of tumor cells in H22 ascites tumor compared with saline control group. Compared with DDP + CY group, The ascitic fluid production decreased; the WBC level in all the groups increased gradually compared with the DDP + CY group, and the dose-response relationship basically appeared. Compared with the control group, the plasma ALT, AST, BUN , ALP and CREA levels showed a decreasing trend. The levels of plasma ALT, AST, BUN and CREA in each dose of tiopronin decreased significantly. Conclusion Tiopronin has a synergistic anti-tumor effect and can reduce adverse reactions such as liver and kidney damage caused by chemotherapy.